Action for Stroke Prevention, an alliance of renowned health experts and patient organizations, has published new reports calling for policy makers and the medical and patient communities to join forces to prevent atrial fibrillation-related strokes. Learn more at: New Report Confirms Europe is on the Brink of a Stroke Crisis
Read More
Today we have a roundup of Atrial Fibrillation Awareness Month stories for you: In her EP Lab DigestPatient Perspective column for this month, StopAfib.org founder Mellanie True Hills summarized the atrial fibrillation stroke prevention report produced by the Afib Optimal Treatment Task Force. There is a lot of great information for patients in this article. …
Read More
Some fascinating new research just reported in the Journal of the American College of Cardiology has shown that atrial fibrillation treatment success more than doubles when patients with medication-resistant high blood pressure [hypertension] and atrial fibrillation have a pulmonary vein isolation catheter ablation augmented by a kidney-related procedure called “renal artery denervation.” To learn more …
Read More
At Heart Rhythm 2012, Dr. James Reiffel gave us an update on new medications for treating atrial fibrillation, including the combination of low doses of ranolazine (Ranexa) and dronedarone (Multaq). He also talked about rate control vs. rhythm control for afib, and how the decision can vary by age and level of symptoms. Watch the …
Read More
The Atrial Fibrillation Optimal Treatment Task Force, led by the Alliance for Aging Research, has just released a consensus statement developed by a group of leading afib stroke prevention experts. We at StopAfib.org are proud to have been part of the development of this consensus statement, which recommends a process for assessing afib stroke and …
Read More
In this video interview recorded at Heart Rhythm 2012, Dr. Eric Prystowsky tackled the controversial topic of rate control vs. rhythm control for treating atrial fibrillation, and knowing whether you are symptomatic or asymptomatic. He also discussed the issues related to leaving afib patients on rate control long term, such as the buildup of fibrosis …
Read More
At Heart Rhythm 2012, Dr. Albert Waldo shared with StopAfib.org’s Mellanie True Hills about why aspirin should no longer be used for the prevention of stroke in atrial fibrillation. Dr. Waldo noted that many global afib guidelines have been revised, or soon will be, to remove aspirin as a recommended atrial fibrillation stroke prevention treatment. …
Read More
At the American College of Cardiology meeting last week, I discovered a neat project being tackled by Alere, the sponsor of PTINR.com, which is a web site we highly recommend for those taking Coumadin or warfarin. If you take warfarin or Coumadin, you know that you have to keep your vitamin K intake consistent, but …
Read More
The wildly beating heart, fatigue and other debilitating symptoms are well known to the many millions of people impacted by atrial fibrillation. Some of those who have afib may have no outward symptoms, but are still at risk of serious and long-term damage to the heart. Symptoms or not, rate control is the common treatment …
Read More
In this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium. He provided an update on rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban, and mentioned that all were better than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the …
Read More